Fragile X Syndrome Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Key Companies - Novartis, Neuren Pharmaceuticals, Roche, Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Lysogene

DelveInsight's "Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fragile X Syndrome, historical and forecasted epidemiology as well as the Fragile X Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Fragile X Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fragile X Syndrome Market Forecast
https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Fragile X Syndrome Market Report:
• The Fragile X Syndrome market size was valued approximately USD 45 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the 7MM, there will be approximately 120,926 people with Fragile X Syndrome who have been diagnosed with the condition overall. A diagnosed prevalent population of 69,798 FXS cases was also present in the United States
• In the US, there were about 28,425 instances of Fragile X Syndrome in women and nearly 41,373 cases of FXS in men in 2021, according to the gender-specific predominant cases
• Key Fragile X Syndrome Companies: Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis, Neuren Pharmaceuticals, Roche, Lysogene, Healx,Confluence Pharmaceuticals, and others
• Key Fragile X Syndrome Therapies: Zygel, Acamprosate, BPN14770, Trofinetide, Sulindac (HLX-0201), zatolmilast, Psilocybin, 1.5 mg, MG01CI, Ganaxolone, AFQ056, STX209, OV101 (gaboxadol), and others
• The Fragile X Syndrome epidemiology based on gender analyzed that males are affected more as compared to females, in the case of Fragile X Syndrome (FXS)
• The Fragile X Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fragile X Syndrome pipeline products will significantly revolutionize the Fragile X Syndrome market dynamics.

Fragile X Syndrome Overview
A CGG trinucleotide expansion in the fragile X mental retardation 1 gene locusXq27.3, also known as a complete mutation (more than 200 CGG repetitions), causes the genetic disorder known as fragile X syndrome (FXS). It causes the gene promoter to become hypermethylated, which silences the gene and lowers the expression of fragile X mental retardation 1, a protein implicated in synaptic plasticity and maturation.

Get a Free sample for the Fragile X Syndrome Market Report
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Fragile X Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Fragile X Syndrome Epidemiology Segmentation:
The Fragile X Syndrome market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Fragile X Syndrome
• Prevalent Cases of Fragile X Syndrome by severity
• Gender-specific Prevalence of Fragile X Syndrome
• Diagnosed Cases of Episodic and Chronic Fragile X Syndrome

Download the report to understand which factors are driving Fragile X Syndrome epidemiology trends @ Fragile X Syndrome Epidemiology Forecast
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Fragile X Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fragile X Syndrome market or expected to get launched during the study period. The analysis covers Fragile X Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Fragile X Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Fragile X Syndrome Therapies and Key Companies
• Zygel: Zynerba Pharmaceuticals
• Acamprosate: Confluence Pharmaceuticals
• BPN14770: Tetra Therapeutics
• Trofinetide: Neuren Pharmaceuticals
• Sulindac (HLX-0201): Healx

Discover more about therapies set to grab major Fragile X Syndrome market share @ Fragile X Syndrome Treatment Market
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Fragile X Syndrome Market Drivers
• Funding and cooperation of various organizations
• Identification of the potential targets by animal models
• Strengthening the molecular basis of Fragile X Syndrome

Fragile X Syndrome Market Barriers
• Failure of Clinical Trials
• Expensive Diagnostic Procedures

Scope of the Fragile X Syndrome Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Fragile X Syndrome Companies: Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis, Neuren Pharmaceuticals, Roche, Lysogene, Healx,Confluence Pharmaceuticals, and others
• Key Fragile X Syndrome Therapies: Zygel, Acamprosate, BPN14770, Trofinetide, Sulindac (HLX-0201), zatolmilast, Psilocybin, 1.5 mg, MG01CI, Ganaxolone, AFQ056, STX209, OV101 (gaboxadol), and others
• Fragile X Syndrome Therapeutic Assessment: Fragile X Syndrome current marketed and Fragile X Syndrome emerging therapies
• Fragile X Syndrome Market Dynamics: Fragile X Syndrome market drivers and Fragile X Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Fragile X Syndrome Unmet Needs, KOL's views, Analyst's views, Fragile X Syndrome Market Access and Reimbursement

To know more about Fragile X Syndrome companies working in the treatment market, visit @ Fragile X Syndrome Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Fragile X Syndrome Market Report Introduction
2. Executive Summary for Fragile X Syndrome
3. SWOT analysis of Fragile X Syndrome
4. Fragile X Syndrome Patient Share (%) Overview at a Glance
5. Fragile X Syndrome Market Overview at a Glance
6. Fragile X Syndrome Disease Background and Overview
7. Fragile X Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Fragile X Syndrome
9. Fragile X Syndrome Current Treatment and Medical Practices
10. Fragile X Syndrome Unmet Needs
11. Fragile X Syndrome Emerging Therapies
12. Fragile X Syndrome Market Outlook
13. Country-Wise Fragile X Syndrome Market Analysis (2019-2032)
14. Fragile X Syndrome Market Access and Reimbursement of Therapies
15. Fragile X Syndrome Market Drivers
16. Fragile X Syndrome Market Barriers
17. Fragile X Syndrome Appendix
18. Fragile X Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Fragile X Syndrome Pipeline
"Fragile X Syndrome Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Fragile X Syndrome market. A detailed picture of the Fragile X Syndrome pipeline landscape is provided, which includes the disease overview and Fragile X Syndrome treatment guidelines.
Fragile X Syndrome Epidemiology
DelveInsight's 'Fragile X Syndrome Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Fragile X Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.